SD230323-098 page 1 of 1

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Certification L17-427-1 | Accreditation #85368

sample Hixotic 2g Jeffrey Alaskan Thunder F*** Disposable

Sample ID SD230323-098 (71079)	Matrix Concentrate (Inhalable Cannabis Good)						
Distributor License 090008555	Address 1007 Grove St, Orange, CA 92865 Name Simple Inc						
Sampled -	Received Mar 23, 2023	Reported Mar 27, 2023					
Analyses executed CANX		Unit Mass (g) 2.0					

Laboratory note: The estimated concentration of the unknown peak in the sample is 6.00% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)88-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC. (+)d8-THC is a different compound from the main (-)d8-THC cannobinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC and d9-THC and d9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)d8-THC and d9-THC with the majority, if not all, of the concentration being (+)d8-THC. Total (+/-) D8 Concentration is estimated to be: 73.44%

CANX - Cannabinoids Analysis

Analyzed Mar 27, 2023 | Instrument HLPC

The expanded Uncertainty of the Cannabinoid analysis is approximately **#.806%** at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND
Cannabidiorcin (CBDO)	0.002	0.007	ND	ND	ND
Abnormal Cannabidiorcin (a-CBDO)	0.01	0.031	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC)	0.012	0.036	ND	ND	ND
11-Hydroxy-∆8-Tetrahydrocannabinol (11-Hyd-∆8-THC)	0.007	0.021	ND	ND	ND
Cannabidiolic Acid (CBDA)		0.16	ND	ND	ND
Cannabigerol Acid (CBGA)		0.16	ND	ND	ND
Cannabigerol (CBG)		0.16	ND	ND	ND
Cannabidiol (CBD)		0.16	ND	ND	ND
1(S)-THD (s-THD)		0.041	ND	ND	ND
1(R)-THD (r-THD)	0.025	0.075	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.001	0.16	ND	ND	ND
Δ 8-tetrahydrocannabivarin (Δ 8-THCV)	0.021	0.064	ND	ND	ND
Cannabidihexol (CBDH)	0.005	0.16	ND	ND	ND
Tetrahydrocannabutol (Δ9-THCB)	0.013	0.038	ND	ND	ND
Cannabinol (CBN)	0.001	0.16	ND	ND	ND
Cannabidiphorol (CBDP)	0.015	0.047	ND	ND	ND
exo-THC (exo-THC)	0.005	0.16	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.003	0.16	UI	UI	UI
Δ 8-tetrahydrocannabinol (Δ 8-THC)		0.16	73.44	734.40	1468.80
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)		0.16	0.34	3.36	6.71
Hexahydrocannabinol (S Isomer) (9s-HHC)		0.16	2.83	28.30	56.59
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)		0.16	4.06	40.63	81.26
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.16	9.10	91.04	182.08
Tetrahydrocannabinolic Acid (THCA)		0.16	ND	ND	ND
Δ 9-Tetrahydrocannabihexol (Δ 9-THCH)		0.071	ND	ND	ND
Cannabinol Acetate (CBNO)		0.043	ND	ND	ND
Δ9-Tetrahydrocannabiphorol (Δ9-THCP)	0.017	0.16	0.21	2.14	4.29
Δ 8-Tetrahydrocannabiphorol (Δ 8-THCP)	0.041	0.16	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.16	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.031	0.094	ND	ND	ND
Δ 9-THC-O-acetate (Δ 9-THCO)	0.066	0.16	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.026	0.079	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.005	0.16	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.067	0.204	ND	ND	ND
Δ 9-THC methyl ether (Δ 9-MeO-THC)			ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			ND	ND	ND
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			77.84	778.39	1556.78
Total CBD (CBDa * 0.877 + CBD)			ND	ND	ND
Total CBG (CBGa * 0.877 + CBG)			ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			11.93	119.34	238.67
Total Cannabinoids			89.99	899.87	1799.73









Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Mon, 27 Mar 2023 11:04:43 -0700

 PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1 This report shall not be encoded except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported an pace greatery to the unless indicated one prevention of the constraints are prevented to be in acceptance with hereing states and included in the constraints and the constraints are prevented one prevention of the constraints of the constraints

QA Testing

